FDA Determines Regulatory Review Period for ADYNOVATE Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of ADYNOVATE, a human biological product, following a submission to the U.S. Patent and Trademark Office (USPTO). This determination is a requirement by law and was made in response to the application submitted by the patent holder.